Current concept of low-grade serous ovarian carcinoma.
作者信息
Nakayama Kentaro, Razia Sultana, Ishibashi Tomoka, Kyo Satoru
机构信息
Department of Obstetrics and Gynecology, Nagoya City University East Medical Center, Nagoya, Japan.
Department of Legal Medicine, Shimane University School of Medicine, Izumo, Japan.
出版信息
Transl Cancer Res. 2024 Jan 31;13(1):6-10. doi: 10.21037/tcr-23-1161. Epub 2024 Jan 25.
Abstract
摘要
相似文献
1
Current concept of low-grade serous ovarian carcinoma.低级别浆液性卵巢癌的当前概念
Transl Cancer Res. 2024 Jan 31;13(1):6-10. doi: 10.21037/tcr-23-1161. Epub 2024 Jan 25.
2
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.低级别浆液性卵巢/腹膜癌的基因组特征及其对临床结局的影响。
Gynecol Oncol. 2022 Jun;165(3):560-567. doi: 10.1016/j.ygyno.2021.11.019. Epub 2022 Mar 30.
3
Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.低级别浆液性卵巢癌和腹膜癌的进展。
Curr Oncol Rep. 2022 Nov;24(11):1549-1555. doi: 10.1007/s11912-022-01315-y. Epub 2022 Aug 13.
4
Advances in precision therapy of low-grade serous ovarian cancer: A review.低级别浆液性卵巢癌精准治疗的进展：综述。
Medicine (Baltimore). 2024 Apr 26;103(17):e34306. doi: 10.1097/MD.0000000000034306.
5
The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction.辅助化疗在晚期低级别浆液性卵巢癌中的不确定获益及手术细胞减灭术的关键作用
J Clin Med. 2021 Dec 17;10(24):5927. doi: 10.3390/jcm10245927.
6
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.晚期低级别浆液性卵巢癌：两个大型肿瘤中心手术及化疗管理的回顾性分析
Front Oncol. 2022 Sep 27;12:970918. doi: 10.3389/fonc.2022.970918. eCollection 2022.
7
Low-grade serous ovarian carcinoma: A comprehensive literature review.低级别浆液性卵巢癌：一篇全面的文献综述。
Aust N Z J Obstet Gynaecol. 2020 Feb;60(1):27-33. doi: 10.1111/ajo.13105. Epub 2019 Dec 17.
8
Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.回顾性分析低级别浆液性卵巢癌的子宫受累情况。
Eur J Obstet Gynecol Reprod Biol. 2024 Mar;294:191-197. doi: 10.1016/j.ejogrb.2024.01.003. Epub 2024 Jan 6.
9
Outcome and prognostic factors of low‑grade serous ovarian cancer: An observational retrospective study.低级别浆液性卵巢癌的结局及预后因素：一项观察性回顾性研究。
Mol Clin Oncol. 2024 May 22;21(1):47. doi: 10.3892/mco.2024.2745. eCollection 2024 Jul.
10
Low-grade Serous Ovarian Carcinoma.低级别浆液性卵巢癌
Geburtshilfe Frauenheilkd. 2018 Oct;78(10):972-976. doi: 10.1055/a-0717-5411. Epub 2018 Oct 19.
引用本文的文献
1
Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer.生殖系统癌症中的分子通路：聚焦前列腺癌和卵巢癌
Cancer Cell Int. 2025 Feb 3;25(1):33. doi: 10.1186/s12935-025-03658-5.
本文引用的文献
1
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.低级别浆液性卵巢癌的全外显子组测序鉴定与临床结局相关的基因组事件。
Gynecol Oncol. 2023 Jul;174:157-166. doi: 10.1016/j.ygyno.2023.04.011. Epub 2023 May 17.
2
Molecular features as promising biomarkers in ovarian cancer.分子特征作为卵巢癌有前途的生物标志物。
Adv Clin Exp Med. 2023 Sep;32(9):1029-1040. doi: 10.17219/acem/159799.
3
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.NOTCH 信号限制低级别浆液性卵巢癌对 MEK 抑制的反应。
Mol Cancer Ther. 2022 Dec 2;21(12):1862-1874. doi: 10.1158/1535-7163.MCT-22-0004.
4
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.低级别浆液性卵巢/腹膜癌的基因组特征及其对临床结局的影响。
Gynecol Oncol. 2022 Jun;165(3):560-567. doi: 10.1016/j.ygyno.2021.11.019. Epub 2022 Mar 30.
5
MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.MAPK 通路遗传改变与低级别浆液性卵巢癌的总生存时间延长相关。
Clin Cancer Res. 2022 Oct 14;28(20):4456-4465. doi: 10.1158/1078-0432.CCR-21-4183.
6
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.曲美替尼对比标准治疗用于复发性低级别浆液性卵巢癌患者（GOG 281/LOGS）：一项国际性、随机、开放标签、多中心、2/3 期临床试验。
Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9.
7
A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.低级别浆液性卵巢癌中激素受体表达的系统评价与荟萃分析
Eur J Obstet Gynecol Reprod Biol. 2021 Jan;256:172-178. doi: 10.1016/j.ejogrb.2020.11.021. Epub 2020 Nov 12.
8
High Frequency of Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients.日本患者低级别浆液性卵巢癌的高频突变
Diagnostics (Basel). 2019 Dec 27;10(1):13. doi: 10.3390/diagnostics10010013.
9
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.EMR 20006-012：一项比较 pimasertib（MEK 抑制剂）联合 SAR245409（PI3K 抑制剂）与单独使用 pimasertib 治疗既往治疗不可切除的交界性或低级别卵巢癌患者的 II 期随机双盲安慰剂对照试验。
Gynecol Oncol. 2020 Feb;156(2):301-307. doi: 10.1016/j.ygyno.2019.12.002. Epub 2019 Dec 20.
10
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.PARAGON 研究：阿那曲唑治疗雌激素受体阳性复发性/转移性低级别卵巢癌和浆液性交界性卵巢肿瘤患者的 II 期研究。
Gynecol Oncol. 2019 Sep;154(3):531-538. doi: 10.1016/j.ygyno.2019.06.011. Epub 2019 Jun 18.
Zotero 插件